Anxiolytic properties of N-acetylcysteine in mice

Behavioural Brain Research

Volumn 317, Issue , 2017, Pages 461-469

  Santos, Patrícia ^a   Herrmann, Ana P ^b   Benvenutti, Radharani ^a   Noetzold, Guilherme ^a   Giongo, Franciele ^a   Gama, Clarissa S ^a,c   Piato, Angelo L ^a   Elisabetsky, Elaine ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DA FRONTEIRA SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Hole board; Light dark; N acetylcysteine (NAC); Open field; Social interaction; Stress induced hyperthermia

Indexed keywords

ACETYLCYSTEINE; DIAZEPAM; ANXIOLYTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CF-1 MOUSE; CONTROLLED STUDY; DRUG EFFECT; ELEVATED T-MAZE TEST; EXPERIMENTAL BEHAVIORAL TEST; HOLE BOARD TEST; LIGHT-DARK TEST; MALE; MOUSE; MOUSE MODEL; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SOCIAL INTERACTION TEST; STRESS INDUCED HYPERTHERMIA TEST; TRANQUILIZING ACTIVITY; ANALYSIS OF VARIANCE; ANIMAL; ANXIETY; BODY TEMPERATURE; COMPLICATION; DARK ADAPTATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; EXPLORATORY BEHAVIOR; FEVER; HUMAN RELATION; MAZE TEST; TIME FACTOR;

ACETYLCYSTEINE; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BODY TEMPERATURE; DARK ADAPTATION; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEVER; INTERPERSONAL RELATIONS; MALE; MAZE LEARNING; MICE; TIME FACTORS;

EID: 84991737454     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.10.010     Document Type: Article

References (70)

1. [1] Pitsikas, N., The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?. Eur. J. Pharmacol. 723 (2014), 181–184, 10.1016/j.ejphar.2013.12.019.
2. [2] Steimer, T., Animal models of anxiety disorders in rats and mice: some conceptual issues. Dialogues Clin. Neurosci. 13 (2011), 495–506.
3. [3] Baxter, A.J., Scott, K.M., Vos, T., Whiteford, H.A., Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol. Med. 43 (2013), 897–910, 10.1017/S003329171200147X.
4. [4] Kessler, G., The economic burden of anxiety and stress disorders. Davis, K.L., Neuropsychopharmacolgy, A.C., (eds.) Neuropsychopharmacol Fifth Gener. Prog., 2002, 981–992.
5. [5] Cryan, J.F., Sweeney, F.F., The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br. J. Pharmacol. 164 (2011), 1129–1161, 10.1111/j.1476-5381.2011.01362.x.
6. [6] Loane, C., Politis, M., Buspirone: what is it all about?. Brain Res. 2012 (1461), 111–118, 10.1016/j.brainres.2012.04.032.
7. [7] Hamner, M.B., Robert, S., Frueh, B.C., Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectr. 9 (2004), 740–752.
8. [8] Van Ameringen, M., Mancini, C., Pipe, B., Bennett, M., Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr. 9 (2004), 753–762.
9. [9] Riaza Bermudo-Soriano, C., Perez-Rodriguez, M.M., Vaquero-Lorenzo, C., Baca-Garcia, E., New perspectives in glutamate and anxiety. Pharmacol. Biochem. Behav. 100 (2012), 752–774, 10.1016/j.pbb.2011.04.010.
10. [10] Furtado, M., Katzman, M.A., Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 229 (2015), 37–48, 10.1016/j.psychres.2015.05.036.
11. [11] Sutherland, A.G., Alexander, D.A., Hutchison, J.D., Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. Cytokine 24 (2003), 219–225.
12. [12] Bouayed, J., Rammal, H., Younos, C., Soulimani, R., Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. Eur. J. Pharmacol. 564 (2007), 146–149, 10.1016/j.ejphar.2007.02.055.
13. [13] de Oliveira, M.R., Silvestrin, R.B., Mello E Souza, T., Moreira, J.C.F., Oxidative stress in the hippocampus, anxiety-like behavior and decreased locomotory and exploratory activity of adult rats: effects of sub acute vitamin A supplementation at therapeutic doses. Neurotoxicology 28 (2007), 1191–1199, 10.1016/j.neuro.2007.07.008.
14. [14] Desrumaux, C., Risold, P.-Y., Schroeder, H., Deckert, V., Masson, D., Athias, A., Laplanche, H., Le Guern, N., Blache, D., Jiang, X.-C., Tall, A.R., Desor, D., Lagrost, L., Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 19 (2005), 296–297, 10.1096/fj.04-2400fje.
15. [15] Berk, M., Malhi, G.S., Gray, L.J., Dean, O.M., The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 34 (2013), 167–177, 10.1016/j.tips.2013.01.001.
16. [16] Dean, O., Giorlando, F., Berk, M., N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. JPN 36 (2011), 78–86, 10.1503/jpn.100057.
17. [17] Berk, M., Jeavons, S., Dean, O.M., Dodd, S., Moss, K., Gama, C.S., Malhi, G.S., Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr. 14 (2009), 357–360.
18. [18] Bernardo, M., Dodd, S., Gama, C.S., Copolov, D.L., Dean, O., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Bush, A.I., Berk, M., Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. Acta Neuropsychiatr. 21 (2009), 285–291, 10.1111/j.1601-5215.2009.00397.x.
19. [19] null Deepmala, J., Slattery, N., Kumar, L., Delhey, M., Berk, O., Dean, C., Spielholz, R., Frye, clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci. Biobehav. Rev. 55 (2015), 294–321, 10.1016/j.neubiorev.2015.04.015.
20. [20] Fernandes, B.S., Dean, O.M., Dodd, S., Malhi, G.S., Berk, M., N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J. Clin. Psychiatry. 77 (2016), e457–466, 10.4088/JCP.15r09984.
21. [21] Wright, D.J., Gray, L.J., Finkelstein, D.I., Crouch, P.J., Pow, D., Pang, T.Y., Li, S., Smith, Z.M., Francis, P.S., Renoir, T., Hannan, A.J., N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease. Hum. Mol. Genet., 2016, 10.1093/hmg/ddw144.
22. [22] Mocelin, R., Herrmann, A.P., Marcon, M., Rambo, C.L., Rohden, A., Bevilaqua, F., de Abreu, M.S., Zanatta, L., Elisabetsky, E., Barcellos, L.J.G., Lara, D.R., Piato, A.L., N-acetylcysteine prevents stress-induced anxiety behavior in zebrafish. Pharmacol. Biochem. Behav. 139 (2015), 121–126, 10.1016/j.pbb.2015.08.006.
23. [23] Durieux, A.M.S., Fernandes, C., Murphy, D., Labouesse, M.A., Giovanoli, S., Meyer, U., Li, Q., So, P.-W., McAlonan, G., Targeting glia with N-acetylcysteine modulates brain glutamate and behaviors relevant to neurodevelopmental disorders in C57BL/6J mice. Front. Behav. Neurosci., 9(343), 2015, 10.3389/fnbeh.2015.00343.
24. [24] Van der Heyden, J.A., Zethof, T.J., Olivier, B., Stress-induced hyperthermia in singly housed mice. Physiol. Behav. 62 (1997), 463–470.
25. [25] Borgström, L., Kågedal, B., Paulsen, O., Pharmacokinetics of N-acetylcysteine in man. Eur. J. Clin. Pharmacol. 31 (1986), 217–222.
26. [26] Ferreira, F.R., Biojone, C., Joca, S.R.L., Guimarães, F.S., Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav. Pharmacol. 19 (2008), 747–750, 10.1097/FBP.0b013e3283123c98.
27. [27] Piato, A.L., Detanico, B.C., Linck, V.M., Herrmann, A.P., Nunes, D.S., Elisabetsky, E., Anti-stress effects of the tonicPtychopetalum olacoides (Marapuama) in mice. Phytomed. Int. J. Phytother. Phytopharm. 17 (2010), 248–253, 10.1016/j.phymed.2009.07.001.
28. [28] Linck, V.M., Costa-Campos, L., Pilz, L.K., Garcia, C.R.L., Elisabetsky, E., AMPA glutamate receptors mediate the antidepressant-like effects of N-acetylcysteine in the mouse tail suspension test. Behav. Pharmacol. 23 (2012), 171–177, 10.1097/FBP.0b013e3283512c3a.
29. [29] Costa-Campos, L., Herrmann, A.P., Pilz, L.K., Michels, M., Noetzold, G., Elisabetsky, E., Interactive effects of N-acetylcysteine and antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 44 (2013), 125–130, 10.1016/j.pnpbp.2013.02.008.
30. [30] Samuni, Y., Goldstein, S., Dean, O.M., Berk, M., The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta 1830 (2013), 4117–4129, 10.1016/j.bbagen.2013.04.016.
31. [31] Zhou, J., Coles, L.D., Kartha, R.V., Nash, N., Mishra, U., Lund, T.C., Cloyd, J.C., Intravenous administration of stable-labeled N-acetylcysteine demonstrates an indirect mechanism for boosting glutathione and improving redox status. J. Pharm. Sci. 104 (2015), 2619–2626, 10.1002/jps.24482.
32. [32] Saitoh, A., Kimura, Y., Suzuki, T., Kawai, K., Nagase, H., Kamei, J., Potential anxiolytic and antidepressant-like activities of SNC80 a selective delta-opioid agonist, in behavioral models in rodents. J. Pharmacol. Sci. 95 (2004), 374–380.
33. [33] Costa-Campos, L., Dassoler, S.C., Rigo, A.P., Iwu, M., Elisabetsky, E., Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacol. Biochem. Behav. 77 (2004), 481–489, 10.1016/j.pbb.2003.12.002.
34. [34] Silverman, J.L., Yang, M., Lord, C., Crawley, J.N., Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 11 (2010), 490–502, 10.1038/nrn2851.
35. [35] Graeff, F.G., Viana, M.B., Tomaz, C., The elevated T maze, a new experimental model of anxiety and memory: effect of diazepam. Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Médicas E Biológicas Soc. Bras. Biofísica Al. 26 (1993), 67–70.
36. [36] Graeff, F.G., Netto, C.F., Zangrossi, H., The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23 (1998), 237–246.
37. [37] Carvalho-Netto, E.F., Nunes-de-Souza, R.L., Use of the elevated T-maze to study anxiety in mice. Behav. Brain Res. 148 (2004), 119–132.
38. [38] Bourin, M., Animal models for screening anxiolytic-like drugs: a perspective. Dialogues Clin. Neurosci. 17 (2015), 295–303 (accessed June 17, 2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610614/.
39. [39] Griebel, G., Holmes, A., 50 years of hurdles and hope in anxiolytic drug discovery. Nat. Rev. Drug Discov. 12 (2013), 667–687, 10.1038/nrd4075.
40. [40] Egashira, N., Shirakawa, A., Abe, M., Niki, T., Mishima, K., Iwasaki, K., Oishi, R., Fujiwara, M., N-acetyl-L-cysteine inhibits marble-burying behavior in mice. J. Pharmacol. Sci. 119 (2012), 97–101.
41. [41] Schneider, R., Santos, C.F., Clarimundo, V., Dalmaz, C., Elisabetsky, E., Gomez, R., N-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats. Alcohol Fayettev. N. 49 (2015), 259–263, 10.1016/j.alcohol.2015.01.009.
42. [42] Bergink, V., van Megen, H.J.G.M., Westenberg, H.G.M., Glutamate and anxiety. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 14 (2004), 175–183, 10.1016/S0924-977X(03)00100-7.
43. [43] Nasca, C., Bigio, B., Zelli, D., Nicoletti, F., McEwen, B.S., Mind the gap: glucocorticoids modulate hippocampal glutamate tone underlying individual differences in stress susceptibility. Mol. Psychiatry 20 (2015), 755–763, 10.1038/mp.2014.96.
44. [44] Koltunowska, D., Gibula-Bruzda, E., Kotlinska, J.H., The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 45 (2013), 242–249, 10.1016/j.pnpbp.2013.04.013.
45. [45] Nicoletti, F., Bockaert, J., Collingridge, G.L., Conn, P.J., Ferraguti, F., Schoepp, D.D., Wroblewski, J.T., Pin, J.P., Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60 (2011), 1017–1041, 10.1016/j.neuropharm.2010.10.022.
46. [46] Swanson, C.J., Bures, M., Johnson, M.P., Linden, A.-M., Monn, J.A., Schoepp, D.D., Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2005), 131–144, 10.1038/nrd1630.
47. [47] Schoepp, D.D., Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299 (2001), 12–20.
48. [48] Dean, O., Giorlando, F., Berk, M., N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. JPN 36 (2011), 78–86, 10.1503/jpn.100057.
49. [49] Najjar, S., Pearlman, D.M., Alper, K., Najjar, A., Devinsky, O., Neuroinflammation and psychiatric illness. J. Neuroinflammation., 10(43), 2013, 10.1186/1742-2094-10-43.
50. [50] Sattler, R., Tymianski, M., Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol. Neurobiol. 24 (2001), 107–129, 10.1385/MN:24:1-3:107.
51. [51] O'Donovan, A., Hughes, B.M., Slavich, G.M., Lynch, L., Cronin, M.-T., O'Farrelly, C., Malone, K.M., Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav. Immun. 24 (2010), 1074–1077, 10.1016/j.bbi.2010.03.003.
52. [52] Salim, S., Asghar, M., Taneja, M., Hovatta, I., Chugh, G., Vollert, C., Vu, A., Potential contribution of oxidative stress and inflammation to anxiety and hypertension. Brain Res. 1404 (2011), 63–71, 10.1016/j.brainres.2011.06.024.
53. [53] Bouayed, J., Rammal, H., Soulimani, R., Oxidative stress and anxiety: relationship and cellular pathways. Oxid. Med. Cell. Longev. 2 (2009), 63–67.
54. [54] Hovatta, I., Tennant, R.S., Helton, R., Marr, R.A., Singer, O., Redwine, J.M., Ellison, J.A., Schadt, E.E., Verma, I.M., Lockhart, D.J., Barlow, C., Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438 (2005), 662–666, 10.1038/nature04250.
55. [55] Masood, A., Nadeem, A., Mustafa, S.J., O'Donnell, J.M., Reversal of oxidative stress-Induced anxiety by inhibition of phosphodiesterase-2 in mice. J. Pharmacol. Exp. Ther. 326 (2008), 369–379, 10.1124/jpet.108.137208.
56. [56] Mattson, M.P., Camandola, S., NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107 (2001), 247–254, 10.1172/JCI11916.
57. [57] Krishna, S., Dodd, C.A., Filipov, N.M., Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration. Behav. Brain Res. 302 (2016), 279–290, 10.1016/j.bbr.2016.01.038.
58. [58] Yang, L., Wang, M., Guo, Y.Y., Sun, T., Li, Y.J., Yang, Q., Zhang, K., Liu, S.B., Zhao, M.G., Wu, Y.M., Systemic inflammation induces anxiety disorder through CXCL12/CXCR4 pathway. Brain. Behav. Immun. 56 (2016), 352–362, 10.1016/j.bbi.2016.03.001.
59. [59] do Nascimento, G.C., Leite-Panissi, C.R.A., Time-dependent analysis of nociception and anxiety-like behavior in rats submitted to persistent inflammation of the temporomandibular joint. Physiol. Behav. 125 (2014), 1–7, 10.1016/j.physbeh.2013.11.009.
60. [60] Kassed, C.A., Herkenham, M., NF-kappaB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety. Behav. Brain Res. 154 (2004), 577–584, 10.1016/j.bbr.2004.03.026.
61. [61] Murphy, Y., Wilson, E., Goldner, E.M., Fischer, B., Benzodiazepine use, misuse, and harm at the population level in Canada: a comprehensive narrative review of data and developments since 1995, clin. Drug Investig. 36 (2016), 519–530, 10.1007/s40261-016-0397-8.
62. [62] Schneider, R., Ottoni, G.L., de Carvalho, H.W., Elisabetsky, E., Lara, D.R., Temperament and character traits associated with the use of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens: evidence from a large Brazilian web survey. Rev Bras. Psiquiatr. São Paulo Braz. 1999 37 (2015), 31–39, 10.1590/1516-4446-2014-1352.
63. [63] Lovick, T.A., Estrous cycle and stress: influence of progesterone on the female brain. Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Médicas E Biológicas Soc. Bras. Biofísica Al. 45 (2012), 314–320.
64. [64] Yang, R., Gallo, D.J., Baust, J.J., Watkins, S.K., Delude, R.L., Fink, M.P., Effect of hemorrhagic shock on gut barrier function and expression of stress-related genes in normal and gnotobiotic mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002), R1263–1274, 10.1152/ajpregu.00278.2002.
65. [65] Beloosesky, R., Weiner, Z., Ginsberg, Y., Ross, M.G., Maternal N-acetyl-cysteine (NAC) protects the rat fetal brain from inflammatory cytokine responses to lipopolysaccharide (LPS). J. Matern. −Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet. 25 (2012), 1324–1328, 10.3109/14767058.2011.632793.
66. [66] Chen, G., Shi, J., Hu, Z., Hang, C., Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm., 5, 2008, 716458 (10.1155/2008/716458.).
67. [67] Khan, M., Sekhon, B., Jatana, M., Giri, S., Gilg, A.G., Sekhon, C., Singh, I., Singh, A.K., Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J. Neurosci. Res. 76 (2004), 519–527, 10.1002/jnr.20087.
68. [68] Wang, X., Svedin, P., Nie, C., Lapatto, R., Zhu, C., Gustavsson, M., Sandberg, M., Karlsson, J.-O., Romero, R., Hagberg, H., Mallard, C., N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann. Neurol. 61 (2007), 263–271, 10.1002/ana.21066.
69. [69] Smaga, I., Pomierny, B., Krzyżanowska, W., Pomierny-Chamioło, L., Miszkiel, J., Niedzielska, E., Ogórka, A., Filip, M., N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 39 (2012), 280–287, 10.1016/j.pnpbp.2012.06.018.
70. [70] Arent, C.O., Valvassori, S.S., Steckert, A.V., Resende, W.R., Dal-Pont, G.C., Lopes-Borges, J., Amboni, R.T., Bianchini, G., Quevedo, J., The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxal sleep deprivation model of mania. J. Psychiatry Res. 65 (2015), 71–79, 10.1016/j.jpsychires.2015.04.011.